Radiopharmaceutical Therapy

Lisa Bodei, MD, PhD is a nuclear medicine physician with extensive experience and expertise in therapeutic and diagnostic applications of nuclear medicine in oncology, particularly with theranostics and the application of genomic technology to further defining the efficacy of theranostics. She is the Director of the Targeted Radionuclide Therapy Section of the Molecular Imaging and Therapy Service in the Department of Radiology, MSKCC. She has authored more than 200 peer-reviewed publications and serves on the editorial boards of several scientific journals.Jason S. Lewis, PhD, is the Emily Tow Chair, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility in the Department of Radiology, MSKCC. He heads a laboratory in the Sloan Kettering Institute’s molecular pharmacology program and is a professor at the Gerstner Sloan Kettering Graduate School of BiomedicalSciences. He has published more than 300 papers, books, book chapters, and reviews on cancer imaging and therapy.Brian M. Zeglis, PhD, received his scientific training at Yale University, the California Institute of Technology, and Memorial Sloan Kettering Cancer Center before starting his own lab at Hunter College of the City University of New York in 2015. His current research is focused on the synthesis, in vivo validation, and clinical translation of radiopharmaceuticals for the imaging and therapy of disease, with a particular emphasis on investigations at the intersection of radiochemistry and bioorthogonal chemistry.

“This is a substantial text extending to more than 550 pages, neatly formatted in the familiar Springer house style and liberally illustrated with photographs and diagrams in both colour and black and white. Individual chapters are sourced from a wide range of authors, in a concerted effort to capture the variation in practice internationally. This is very welcome … . I would recommend this as a reference text for any nuclear medicine department … .” (Heather Williams, RAD Magazine, September, 2024)“There are no other books like this for those who want to learn or update themselves on the state of the art and the future of radiopharmaceutical therapy … . I very strongly suggest this publication not only to nuclear physicians … but also to all oncologists and other clinicians interested in the topic and to scientists and students who want to look for an extremely promising field of development for their future research or clinical practice.” (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51 (4), 2024)

• Preface.- Foreword.- Section 1. Fundamentals.- Chapter 1. Introduction: The Case for Endoradiotherapy.- Chapter 2. The History of Endoradiotherapy.- Chapter 3. The Nuclear Chemistry of Therapeutic Radionuclides.- Chapter 4. The Production of Therapeutic Radionuclides.- Chapter 5. The Radiobiology of Alpha Particles, Beta Particles, and Auger Electrons.- Chapter 6. The Radiopharmaceutical Chemistry of Metallic Radionuclides.- Chapter 7. The Radiopharmaceutical Chemistry of Non-Metallic Radionuclides.- Chapter 8. Dosimetry in Endoradiotherapy.- Section 2. Deeper Dives.- Chapter 9. Antibodies as Vectors for Endoradiotherapy.- Chapter 10. Case Study #1: 225Ac-Labeled IgG.- Chapter 11. Case Study #2: 131I-3F8.- Chapter 12. Case Study #3: Antibody Fragments in Endoradiotherapy.- Chapter 13. Peptides as Vectors for Endoradiotherapy.- Chapter 14. Case Study #4: LUTATHERA.- Chapter 15. Case Study #5: CXCR4.- Chapter 16. Case Study #6: JR11.- Chapter 17. Small Molecules as Vectors for Endoradiotherapy.- Chapter 18. Case Study #7: PSMA-617.- Chapter 19. Case Study #8: 223RaCl3.- Section 3. Special Topics.- Chapter 20. Auger Emitters in Endoradiotherapy.- Chapter 21. In Vivo Pretargeting.- Chapter 22. Theranostic Imaging and Endoradiotherapy.- Chapter 23. The Next Generation of Therapeutic Radionuclides.- Chapter 24. Artificial Intelligence and Machine Learning.- Chapter 25. The Regulatory Review of Radiotherapeutics: USA.- Chapter 26. The Regulatory Review of Radiotherapeutics: Europe.- Chapter 27. The Regulatory Review of Radiotherapeutics: Japan.- Chapter 28. Radiotherapeutics in the Nuclear Pharmacy.- Chapter 29. The Future.